News

€70m fund for EU biotechs
Enlarge image

BusinessEUGermanySwitzerlandUKAustria

€70m fund for EU biotechs

20.09.2012 - The European VC firm Wellington Partners has announced the first closing of a fund exclusively dedicated to investments in EU life sciences companies.

Money for life science companies is coming back to Europe. After Edmond de Rothschild Investment Partners scored €125m for its fourth life sciences fund and Index Ventures announced to put €150m into life sciences companies, now, Wellington Partners (London, Zurich, Munich) has attracted commitments of over  €70m  for its new Wellington Partners IV Life Science Fund. With a target size of €120m, the venture capitalists expect it to be significantly larger than the previous Wellington Partners III Life Science Fund, which raised €78m. Investments will focus on European companies developing innovative medical devices, diagostics and biotechnology.

According to Wellington’s investment team, the new fund attracted investors from Germany, Switzerland, Austria, Benelux, France, the UK, the US and the Middle East, among them the European Investment Fund (EIF), LfA Förderbank Bayern, Austria Wirtschaftsservice GmbH and certain large family offices.

Dr. Rainer Strohmenger, General Partner at Wellington Partners, said that the closing was a "big success in a challenging financial environment". For investors who are willing to act anti-cyclically, the sector would „provide the opportunity to generate outstanding returns.“

Wellington Partners’ portfolio already comprises some successful European life sciences players, amongst them Swiss Actelion or German mtm laboratories, which was swallowed by Roche last year for up to €190m. Other players include: Cancer vaccine developer immatics, medtech company Invendo Medical, diagnostics specialist Oxford Immunotec, and heart valve developer Symetis. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-03/wellington-partners-closes-eur70m-fund.html

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

M&AIreland

31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%

FLOP

  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%

TOP

  • MEDIGENE12.90 EUR93.4%
  • 4SC1.18 EUR66.2%
  • FORMYCON31.00 EUR37.7%

FLOP

  • CYTOS1.28 CHF-14.7%
  • MORPHOSYS60.74 EUR-12.8%
  • BB BIOTECH281.20 EUR-11.3%

TOP

  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%

FLOP

  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 17.04.2015